Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:6:p9
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 6 (pt 9/36)
Character Range: 333507–336392

caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or

       (d) in preparations for external use; or

       (e) in other preparations with a concentration of less than 5% of caffeine.
    CAJUPUT OIL except:

       (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

       (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

       (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

          (i) KEEP OUT OF REACH OF CHILDREN; and

          (ii) NOT TO BE TAKEN; or

       (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

          (i) KEEP OUT OF REACH OF CHILDREN; and

          (ii) NOT TO BE TAKEN; or

       (e) in preparations containing 25% or less of cajuput oil; or

       (f) in oils containing 25% or less of cajuput oil.
    CALCIFEROL in rodent baits containing 0.1% or less of calciferol.
    CAMBENDAZOLE.
    CAMPHOR except:

       (a) when included in Schedule 4 or 5; or

       (b) when enclosed in an inhaler device which prevents ingestion of its contents; or

       (c) in solid or semi‑solid preparations containing 12.5% or less of camphor; or

       (d) in liquid preparations containing 2.5% or less of camphor; or

       (e) in essential oils when the camphor is present as a natural component of the oil:

          (i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

          (ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

          (iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

             (A) KEEP OUT OF REACH OF CHILDREN;